ALNY vs. DHR: Alnylam Pharmaceuticals vs. Danaher Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Danaher (DHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Danaher (DHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while DHR is classified in Life Sciences Tools & Services.
| Profile Item | ALNY | DHR |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Danaher Corp. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 20.89 billion USD | 161.86 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2004 | December 29, 1978 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | DHR |
|---|---|---|
| Total Return (1Y) | -64.57% | 11.88% |
| Total Return (3Y, Annualized) | -1.58% | 6.67% |
| Total Return (5Y, Annualized) | -3.13% | -2.05% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | DHR |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 30.61% |
| Beta (5Y) | 0.45 | 0.76 |
| Max Drawdown (5Y) | -68.25% | -43.31% |
| Avg. Volume (3M) | 1.90M | 3.94M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | DHR |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.25 |
| Sortino Ratio (1Y) | -1.45 | 0.35 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Danaher (DHR) at 8.19% also sits in the top quartile.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 109.18%
- DHR
- 8.19%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Danaher (DHR) at 16.91% also retains a top-quartile share.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.91%
- Max
- 18.05%
- DHR
- 16.91%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Danaher (DHR) at 21.13% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.13%
- Max
- 83.12%
- DHR
- 21.13%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | DHR |
|---|---|---|
| ROE (TTM) | 138.07% | 8.19% |
| ROA (TTM) | 9.51% | 4.06% |
| Net Margin (TTM) | 52.85% | 16.91% |
| Operating Margin (TTM) | 23.72% | 21.13% |
| Gross Margin (TTM) | 77.28% | 59.36% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Danaher (DHR) at 2.90% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: Danaher (DHR) reports EPS growth of -4.54%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | DHR |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 2.90% |
| Revenue Growth (3Y CAGR) | 52.98% | -2.67% |
| EPS Growth (YoY) | -- | -4.54% |
| EPS Growth (3Y CAGR) | -- | -19.44% |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- DHR
- 1.63
- Min
- 0.10
Debt / Equity (MRQ)
Danaher (DHR) at 0.52 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.52
- Max
- 1.42
- Q3
- 0.65
- DHR
- 0.52
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | DHR |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 1.63 |
| Debt / Equity (MRQ) | 0.83 | 0.52 |
| Net Debt / EBITDA | -0.57 | 2.68 |
Dividends
Dividend Yield (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67%
- DHR
- 0.67%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.17%
- DHR
- 25.17%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | DHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.67% |
| Dividend Payout Ratio (TTM) | 0.00% | 25.17% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Danaher (DHR) at 38.12 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.12
- Max
- 85.34
- Q3
- 43.46
- DHR
- 38.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Danaher (DHR) at 6.32 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.32
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- DHR
- 6.32
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Danaher (DHR) at 3.02 are valued close to their industries’ norm against book — neither stands out from peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.02
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- DHR
- 3.02
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | DHR |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 38.12 |
| P/S Ratio (TTM) | 4.17 | 6.32 |
| P/B Ratio (MRQ) | 5.79 | 3.02 |
| Free Cash Flow Yield (TTM) | 1.57% | 2.93% |